Roth Comments on Regeneron (REGN), Sanofi Presentation of Sarilumab Phase 3 Data; Affirms at 'Buy'

Roth Capital comments on Regeneron (Nasdaq: REGN) after it and Sanofi presented positive results from a phase 3 trial of investigational drug sarilumab in rheumatoid arthritis (RA) patients who were inadequate responders to methotrexate (MTX) therapy.

Analyst Joseph Pantginis said, Of note is that the 200mg group showed a 90 percent reduction of structural damage compared to placebo at week 52 as assessed by radiography. The secondary endpoint was major clinical response (MCR) defined as a 70 percent or more reduction of RA signs and symptoms. The results show a MCR of 13 percent (150mg), 15 percent (200mg) and 3 percent (placebo).

Pantginis has Regeneron at Buy with a price target of $382, saying, We believe REGN has solid growth prospects based on: 1) approved and late stage products, 2) a deep pipeline, 3) expansion of indications for current products, 4) strong partners and, 5) strong cash management.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Regeneron Pharma closed at $310.24 yesterday.

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $1,030 at TD Cowen
• Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
• Opthea Ltd. (OPT) PT Raised to $18 at Oppenheimer